Drug Approval | April 28, 2025
CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
The 27 greenfield labs across the country ensure timely and accurate reporting
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
The system is powered by advanced imaging innovations such as Amber-red Color Imaging, Triple Noise Reduction, and Extended Dynamic Range Image Processing
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Subscribe To Our Newsletter & Stay Updated
